[go: up one dir, main page]

BRPI0821115A8 - Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto - Google Patents

Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto

Info

Publication number
BRPI0821115A8
BRPI0821115A8 BRPI0821115A BRPI0821115A BRPI0821115A8 BR PI0821115 A8 BRPI0821115 A8 BR PI0821115A8 BR PI0821115 A BRPI0821115 A BR PI0821115A BR PI0821115 A BRPI0821115 A BR PI0821115A BR PI0821115 A8 BRPI0821115 A8 BR PI0821115A8
Authority
BR
Brazil
Prior art keywords
compound
drug
pharmaceutical composition
aminotriazole
aminotriazole derivative
Prior art date
Application number
BRPI0821115A
Other languages
English (en)
Inventor
Grisostomi Corinna
Cren Sylvaine
Leroy Xavier
Bur Daniel
Corminboeuf Olivier
Richard-Bildstein Sylvia
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0821115A2 publication Critical patent/BRPI0821115A2/pt
Publication of BRPI0821115A8 publication Critical patent/BRPI0821115A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO DERIVADO DE AMINOTRIAZOL, MEDICAMENTO, COMPOSIÇÃO FARMACÊUTICA E USO DO COMPOSTO. Refere-se a presente invenção aos derivados de aminotriazol da fórmula (I), em que A, E, R1 e R2 são tais como definidos na descrição, sua preparação e seu uso como compostos farmaceuticamente ativos. Os compostos são de utilidade para a prevenção ou tratamento de enfermidades, as quais reagem à modulação do receptor de ALX, tais como enfermidades inflamatórias.
BRPI0821115A 2007-12-18 2008-12-17 Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto BRPI0821115A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007055199 2007-12-18
IB2008054369 2008-10-23
PCT/IB2008/055375 WO2009077990A1 (en) 2007-12-18 2008-12-17 Aminotriazole derivatives as alx agonists

Publications (2)

Publication Number Publication Date
BRPI0821115A2 BRPI0821115A2 (pt) 2015-06-16
BRPI0821115A8 true BRPI0821115A8 (pt) 2017-12-26

Family

ID=40404773

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821115A BRPI0821115A8 (pt) 2007-12-18 2008-12-17 Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto

Country Status (25)

Country Link
US (1) US8536209B2 (pt)
EP (1) EP2225231B1 (pt)
JP (1) JP4656674B2 (pt)
KR (1) KR101213007B1 (pt)
CN (1) CN101903378B (pt)
AR (1) AR069801A1 (pt)
AT (1) ATE520689T1 (pt)
AU (1) AU2008337097B2 (pt)
BR (1) BRPI0821115A8 (pt)
CA (1) CA2706839C (pt)
CY (1) CY1112465T1 (pt)
DK (1) DK2225231T3 (pt)
HR (1) HRP20110825T1 (pt)
IL (1) IL206399A (pt)
MA (1) MA31949B1 (pt)
MX (1) MX2010006241A (pt)
MY (1) MY153985A (pt)
NZ (1) NZ586735A (pt)
PL (1) PL2225231T3 (pt)
PT (1) PT2225231E (pt)
RU (1) RU2492167C2 (pt)
SI (1) SI2225231T1 (pt)
TW (1) TWI434685B (pt)
WO (1) WO2009077990A1 (pt)
ZA (1) ZA201005080B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
SI2432760T1 (sl) 2009-05-18 2013-10-30 Actelion Pharmaceuticals Ltd. Premoĺ äśeni derivati spiro (2.4) heptana kot alx-receptorji in/ali fprl2-agonisti
NZ597453A (en) 2009-06-09 2013-03-28 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives as alxr agonists
CN102803237B (zh) * 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物
CN103221392B (zh) 2010-11-17 2015-06-03 埃科特莱茵药品有限公司 桥联螺[2.4]庚酯衍生物
JP5923107B2 (ja) * 2010-12-07 2016-05-24 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのオキサゾリル−メチルエーテル誘導体
CA2816406C (en) * 2010-12-07 2019-02-26 Actelion Pharmaceuticals Ltd Hydroxylated aminotriazole derivatives as alx receptor agonists
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN102558117B (zh) * 2011-12-15 2014-10-08 北京金骄生物质化工有限公司 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
TW201348219A (zh) 2012-05-16 2013-12-01 Actelion Pharmaceuticals Ltd 作爲ａｌｘ受體激動劑之經１－（對－甲苯基）環丙基取代橋聯螺［２．４］庚烷衍生物
TWI510481B (zh) 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd 苯并咪唑脯胺酸衍生物
MX2015004638A (es) 2012-10-10 2015-07-14 Actelion Pharmaceuticals Ltd Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-) aril]-[2-meta bi-(hetero-) aril)-pirrolidin-1-il]-metanona.
BR112015012885A2 (pt) * 2012-12-03 2017-07-11 Hoffmann La Roche composições triazol e imidazol substituídas
JP2016510810A (ja) 2013-03-12 2016-04-11 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
RU2016105310A (ru) 2013-07-18 2017-08-23 Актелион Фармасьютиклз Лтд Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
EP3075726B1 (en) 2013-11-28 2017-11-08 Kyorin Pharmaceutical Co., Ltd. Urea derivatives or pharmacologically acceptable salts thereof useful as formyl peptide receptor like 1 (fprl-1) agonists
LT3077391T (lt) 2013-12-04 2018-10-25 Idorsia Pharmaceuticals Ltd Benzimidazolo prolino darinių panaudojimas
KR20180006450A (ko) 2015-05-27 2018-01-17 교린 세이야꾸 가부시키 가이샤 우레아 유도체 또는 그의 약리학상 허용되는 염
EP3303284B1 (en) 2015-05-27 2020-04-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
KR20180081528A (ko) * 2015-11-24 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
JP7743010B2 (ja) * 2021-03-12 2025-09-24 国立大学法人 長崎大学 ハロカルボニル化合物の製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
WO2003035006A2 (en) 2001-10-26 2003-05-01 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Amyloid ss is a ligand for fpr class receptors
AU2003214249A1 (en) 2002-04-03 2003-10-13 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
WO2005047899A2 (en) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
CN101115728B (zh) * 2004-12-13 2012-12-19 利奥制药有限公司 三唑取代的氨基二苯甲酮化合物
AU2006312083A1 (en) * 2005-11-03 2007-05-18 Merck Sharp & Dohme Corp. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
EP2024342A2 (en) * 2006-05-01 2009-02-18 Pfizer Products Incorporated Substituted 2-amino-fused heterocyclic compounds
CA2982520A1 (en) 2007-08-21 2009-02-26 Senomyx, Inc. Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
SI2432760T1 (sl) 2009-05-18 2013-10-30 Actelion Pharmaceuticals Ltd. Premoĺ äśeni derivati spiro (2.4) heptana kot alx-receptorji in/ali fprl2-agonisti
NZ597453A (en) 2009-06-09 2013-03-28 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives as alxr agonists
CN102803237B (zh) 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物

Also Published As

Publication number Publication date
EP2225231A1 (en) 2010-09-08
PL2225231T3 (pl) 2012-01-31
CN101903378A (zh) 2010-12-01
RU2492167C2 (ru) 2013-09-10
US20100331378A1 (en) 2010-12-30
ATE520689T1 (de) 2011-09-15
PT2225231E (pt) 2011-10-19
MY153985A (en) 2015-04-30
DK2225231T3 (da) 2011-10-17
HRP20110825T1 (hr) 2011-12-31
KR20100092516A (ko) 2010-08-20
WO2009077990A1 (en) 2009-06-25
IL206399A0 (en) 2010-12-30
TW200932216A (en) 2009-08-01
CN101903378B (zh) 2014-03-12
JP2011506594A (ja) 2011-03-03
EP2225231B1 (en) 2011-08-17
KR101213007B1 (ko) 2012-12-20
BRPI0821115A2 (pt) 2015-06-16
ZA201005080B (en) 2011-12-28
MA31949B1 (fr) 2010-12-01
US8536209B2 (en) 2013-09-17
CY1112465T1 (el) 2015-12-09
IL206399A (en) 2016-03-31
TWI434685B (zh) 2014-04-21
MX2010006241A (es) 2010-06-30
SI2225231T1 (sl) 2011-12-30
NZ586735A (en) 2012-06-29
AR069801A1 (es) 2010-02-17
AU2008337097A1 (en) 2009-06-25
HK1144158A1 (en) 2011-01-28
CA2706839A1 (en) 2009-06-25
JP4656674B2 (ja) 2011-03-23
RU2010129272A (ru) 2012-01-27
CA2706839C (en) 2015-10-20
AU2008337097B2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
UY30759A1 (es) Compuestos quimicos
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BR112012031561A2 (pt) morfolino pirimidinas e seu uso em terapia.
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
BRPI0716171A8 (pt) Composto, composição farmacêutica e uso de um composto
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0918750B8 (pt) derivado de 2-carboxamida cicloamino ureia, seu uso e sua composição farmacêutica
BRPI1008473A2 (pt) compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
ATE530524T1 (de) Substituierte sulfonamid-derivate
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112012011793A2 (pt) "acrilamidas heterocíclicas e seu uso como farmacêuticos"
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.